Skip to main content
Premium Trial:

Request an Annual Quote

CXR Biosciences, Wyeth Collaborate on $6.2M Drug Toxicity Marker Study

NEW YORK (GenomeWeb News) – The Scottish company CXR Biosciences said today it will work with the University of Dundee and Wyeth Pharmaceuticals in a £3 million ($6.2 million) collaboration to seek protein biomarkers that indicate the toxic effects of certain drugs.
 
CXR Bio said the three-year project is co-funded by the Technology Strategy Board and will be conducted in part by Wyeth scientists and by core lab staff at the Translational Medicine Research Center in Dundee.
 
The study intends to identify these markers and then develop assays to measure possible toxic effects of new drugs before they develop.
 
These assays then would be used in the lab to identify drug candidates that present too high of a risk to human safety to be advanced into clinical trials. They also could be used to give warnings of drugs that could lead to harm if the treatment is continued or if the dosing is increased, the company said. 
 
CXR Bio did not provide details about who will have ownership of intellectual property resulting from the collaboration.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.